LogicBio Therapeutics Inc

NASDAQ:LOGC   3:59:43 PM EDT
4.07
+0.04 (+0.99%)
Products, Regulatory, Other Pre-Announcement

Logicbio Therapeutics Announces First Patient Dosed In Groundbreaking Phase 1/2 Sunrise Clinical Trial For The Treatment Of Pediatric Patients Suffering From Methylmalonic Acidemia

Published: 06/02/2021 11:43 GMT
LogicBio Therapeutics Inc (LOGC) - Logicbio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 Sunrise Clinical Trial for the Treatment of Pediatric Patients Suffering From Methylmalonic Acidemia.
Logicbio Therapeutics Inc - on Track to Announce Update on Enrollment, Dose Escalation and Age De-escalation in Late 2021.
Logicbio Therapeutics Inc - Expects Interim Data From Trial by Year-end 2021.